Mabswitch Receives Second NCI SBIR Award to Advance Programmable Therapeutics

Mabswitch Inc., (Mabswitch) today announced that it has received a second Small Business Innovation Research (SBIR) Phase I award from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to advance its remote-controlled Peptide-Centric CAR (PC-CAR) T-cell therapy program for hard-to-treat solid tumors. The program will be conducted in collaboration with Dr. Mark Yarmarkovich and his research group at New York University (NYU).

Mabswitch wins Best Breakthrough Award

At a Pitch Day competition in Los Angeles hosted by GeneOnline US in collaboration with the Taiwan Biomedical Innovation Association (TiBIA), aimed at discovering transformative start-ups that could revolutionize the field, Mabswitch Inc. was awarded the “Best Breakthrough Award“. The event showcased breakthrough discoveries and partnerships in biotechnology and offered Read more

Mabswitch Receives Prestigious SBIR Phase 1 Award from National Cancer Institute for Innovative SaefCAR Immunotherapy Project

Los Angeles, CA – Mabswitch Inc, a pioneering biotechnology company at the forefront of cutting-edge cancer immunotherapies, is proud to announce that it has been awarded a Small Business Innovation Research (SBIR) Phase 1 grant by the National Cancer Institute (NCI). This grant will support Mabswitch’s groundbreaking project, titled “SaefCAR: Read more

MabSwitch is an Awardee of the 2021 CLSA Inspire QuickFire Challenge for Diverse Innovators

MabSwitch™ is an awardee of the 2021 Inspire QuickFire Challenge for Diverse Innovators for its approach to create innovative solutions for patients. The Inspire QuickFire Challenge is a joint program of California Life Sciences Association (CLSA), the trade association representing California’s life sciences sector, AbbVie, 5AM Ventures, and Johnson & Johnson Read more